US EditionBiogen will stop selling its controversial Alzheimer’s drug Aduhelm
- Biogen has announced that it will discontinue the sale and development of the Alzheimer's drug Aduhelm, refocusing efforts on their newly approved drug Leqembi.
- The decision to drop Aduhelm is not due to safety or efficacy concerns, and the Swiss company Neurimmune will regain full rights to the medicine.
- Biogen will redistribute resources from Aduhelm to other Alzheimer's treatments in their portfolio, such as BIIB080.
76 Articles
76 Articles
Biogen drops controversial Alzheimer's drug, focuses on other treatments
Biogen said it is discontinuing its controversial drug Aduhelm, so it can focus resources on other Alzheimer’s treatments that drive long-term growth.This includes shifting its priorities to its blockbuster drug Leqembi, which was developed with Japan's Eisai and approved in 2023."As a pioneer in Alzheimer’s disease, Biogen is reprioritizing resources to build a leading franchise to address the multiple pathologies of the disease and patient nee…
The FDA, the American regulatory body, had granted accelerated approval to Aduhelm in the USA in June 2021. A controversial drug that was announced as a pioneer in the treatment of cognitive decline associated with Alzheimer's disease, was withdrawn from the market. The announcement was made by the manufacturer itself, the biotechnology company Biogen. Biogen said it would suspend manufacturing, distribution, and sales of the drug Aduhelm to ded…
Coverage Details
Bias Distribution
- 65% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
